Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06214611 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospective Validation of Adaptive Radiotherapy (ART) in Patients With Head and Neck Tumors

Study acronym: ART in HNT
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 27, 2024 (before its estimated December 15, 2024 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Dec 15, 2024 to Dec 15, 2027v4
  2. Secondary endpoints: 6 to 8v3
  3. Secondary endpoints: details revised at 2 of 6 entriesv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Adaptive radiotherapy (ART) includes image-guided radiotherapy (IGRT) and also offers further possibilities for plan adaptation. A particularly high benefit can be expected for patients in whom the clinical target volume (CTV) can show a significant change in shape from fraction to fraction due to anatomical deviations. The shape and position constancy of the CTV during the course of the series is examined in this trial. Dosimetric disadvantages of this type have not been reported so far. The aim of this study is to identify patients who benefit from ART at an early stage and to select them for this method, and then to continue to offer ART to this patient group. If a relevant reduction in the minimum planning target volume (PTV) margins with ART compared to IGRT is demonstrated in this study, patients could be treated with ART.
Trial Details
NCT Number NCT06214611
Lead Sponsor University Hospital, Essen
Conditions
(from sponsor)		 Head and Neck Cancer, Adaptive Radiotherapy, Radiation, Optimized Treatment, Protection of Organs at Risk, Dysphagia Reduction
Related terms Head and Neck Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov